Dr William Jenkins appointed as Independent Non-Executive Director Recent board roles include Ablynx, BTG, Evotec

HASSELT, Belgium, and CHEPSTOW, UK, 7th March 2018

Apitope, a clinical stage biotech company developing potential first-in-class antigen-specific immunotherapies targeting autoimmune diseases, today announced the appointment of William Jenkins, M.D., as Independent Non-Executive Director to its Board.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...